Trial begins with drug to treat severe COVID-19 pneumonia

April 15, 2021

Trial begins with drug to treat severe COVID-19 pneumonia

A study just underway at UW Medicine is evaluating whether a lab-formulated monoclonal antibody could curb the over-amplified inflammatory response that some patients experience with COVID-19 pneumonia.  The researchers are evaluating the drug's ability to improve patients' recoveries. 

"We hope that this antibody will dampen inflammation in patients with severe COVID-19 pneumonia – people who need extra oxygen ... and hasten the improvement to where people are able to get off of (assisted) oxygen," said Dr. Mark Wurfel, a pulmonary and critical care specialist at UW Medicine in Seattle. 

The physician-researchers base their hope on evidence that the antibody helped reduce inflammation among people suffering from acute respiratory distress syndrome, or ARDS. 

The research trial is being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Find details on the study in this news release.


Terms of appropriate usage of file downloads

  • News reporters and news organizations may freely republish and distribute videos, still images and audio files produced by UW Medicine and the University of Washington School of Medicine.
  • Works must be attributed/credited appropriately (for example, “UW Medicine” – as denoted in the file) and must not be used for commercial purposes.
  • These visual and audio files may not be used to exploit or misrepresent UW Medicine or the University of Washington.
  • UW Medicine often licenses still images and stock video from Getty Images, but we cannot grant republishing rights. You may not republish single image files, videos or animations credited to Getty Images.
  • Logos of UW Medicine and University of Washington Health Sciences schools may not be republished without explicit permission. Contact us by phone or email: 206.543.3620 or